257 related articles for article (PubMed ID: 12798702)
1. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Sugiyama T; Yakushiji M; Noda K; Ikeda M; Kudoh R; Yajima A; Tomoda Y; Terashima Y; Takeuchi S; Hiura M; Saji F; Takahashi T; Umesaki N; Sato S; Hatae M; Ohashi Y
Oncology; 2000; 58(1):31-7. PubMed ID: 10644938
[TBL] [Abstract][Full Text] [Related]
3. A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Ren Y; Li Y; Liu J
Int J Gynecol Cancer; 2011 May; 21(4):685-9. PubMed ID: 21543932
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Muggia FM; Blessing JA; McGehee R; Monk BJ
Gynecol Oncol; 2004 Aug; 94(2):483-7. PubMed ID: 15297192
[TBL] [Abstract][Full Text] [Related]
6. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Xiong Y; Liang LZ; Cao LP; Min Z; Liu JH
Gynecol Oncol; 2011 Oct; 123(1):99-104. PubMed ID: 21741694
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
[TBL] [Abstract][Full Text] [Related]
9. [Clinical effects of combination chemotherapy with irinotecan hydrochloride and cisplatin on cervical cancer: study of 46 patients].
Wang CY; Ma D; Zhu T; Chen SY; Zhang QH; Song XJ; Chen TH; Gu MJ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2104-8. PubMed ID: 16313818
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
11. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
12. Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.
Ohara T; Kobayashi Y; Yoshida A; Yoshioka N; Yahagi N; Kondo H; Tozawa A; Kiguchi K; Suzuki N
Int J Clin Oncol; 2013 Dec; 18(6):1102-6. PubMed ID: 23095879
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
14. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Dimopoulos MA; Papadimitriou CA; Sarris K; Aravantinos G; Kalofonos C; Gika D; Gourgoulis GM; Efstathiou E; Skarlos D; Bafaloukos D
Gynecol Oncol; 2002 Jun; 85(3):476-82. PubMed ID: 12051877
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
16. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
Gilbert J; Cmelak A; Shyr Y; Netterville J; Burkey BB; Sinard RJ; Yarbrough WG; Chung CH; Aulino JM; Murphy BA
Cancer; 2008 Jul; 113(1):186-92. PubMed ID: 18484593
[TBL] [Abstract][Full Text] [Related]
19. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Lhommé C; Fumoleau P; Fargeot P; Krakowski Y; Dieras V; Chauvergne J; Vennin P; Rebattu P; Roche H; Misset JL; Lentz MA; Van Glabbeke M; Matthieu-Boué A; Mignard D; Chevallier B
J Clin Oncol; 1999 Oct; 17(10):3136-42. PubMed ID: 10506610
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.
Eralp Y; Saip P; Sakar B; Tas F; Aydiner A; Topuz E
Eur J Gynaecol Oncol; 2003; 24(3-4):323-6. PubMed ID: 12807249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
